Hong Xie

发表

Abstract 2563: Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma

C. McCudden, A. Axel, B. Hall, 2014 .

Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach

D. Ouellet, N. Haddish-Berhane, Hong Xie, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

P. Sonneveld, S. Jagannath, A. Krishnan, 2013, British journal of haematology.

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

A. Palumbo, J. Laubach, H. van de Velde, 2014, Blood.

Blockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

Michael L. Wang, D. Kuhn, M. Cornfeld, 2011, British journal of haematology.

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, J. Cavenagh, H. van de Velde, 2015, American journal of hematology.

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

J. Blay, P. Hammerman, A. Italiano, 2016 .

Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.

S. Lonial, A. Oriol, N. Lavi, 2020, Clinical lymphoma, myeloma & leukemia.

Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).

R. Govindan, J. Tabernero, J. Soria, 2017 .

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

P. Ascierto, R. Plummer, E. Felip, 2022, Cancer Chemotherapy and Pharmacology.

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

R. Govindan, A. Italiano, J. Tabernero, 2019, Clinical Cancer Research.

Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

J. Rossi, P. Sonneveld, S. Jagannath, 2007 .

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.

N. Agarwal, E. Attiyeh, A. Hansen, 2023, Clinical genitourinary cancer.

Erratum to: MEKC-LIF for Sensitive Discrimination of Six Potential Risk Predictors for Auxiliary Diagnosis of Anesthesia Complications in Clinical Urine Fluids

Hong Xie, Yanhong Shang, Xiuhua Zhao, 2016, Chromatographia.

Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors

J. Pérez-Ruixo, D. Ouellet, A. Dosne, 2019, Cancer Chemotherapy and Pharmacology.

A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,

P. Sonneveld, S. Jagannath, A. Krishnan, 2011 .

IL-6) in multiple myeloma - without siltuximab (anti Phase 2 randomized study of bortezomib-melphalan-prednisone with or

A. Palumbo, J. Laubach, R. Orlowski, 2014 .